# Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)

> **NCT03315689** · PHASE2 · COMPLETED · sponsor: **Aclaris Therapeutics, Inc.** · enrollment: 11 (actual)

## Conditions studied

- Alopecia Universalis (AU)
- Alopecia Totalis (AT)

## Interventions

- **DRUG:** Vehicle
- **DRUG:** ATI-50002

## Key facts

- **NCT ID:** NCT03315689
- **Lead sponsor:** Aclaris Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-14
- **Primary completion:** 2019-06-20
- **Final completion:** 2019-06-20
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2020-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03315689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03315689, "Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03315689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*